104265-58-9 Usage
Tosylate ester
p-toluenesulfonate ester
A functional group present in the compound, which is derived from a p-toluenesulfonic acid and an alcohol, providing specific reactivity and stability.
Fluorine substituent
A fluorine atom attached to the compound, which can influence the reactivity, polarity, and lipophilicity of the molecule.
Hydroxyl substituent
A hydroxyl group (-OH) present in the compound, which can participate in hydrogen bonding and affect the solubility and reactivity of the molecule.
Use in chemical and pharmaceutical research
The compound is often used as a reagent or intermediate for synthesis in various research applications due to its unique structural properties and potential functions.
Specific structural properties
The compound's structure, including the arrangement of atoms and functional groups, contributes to its unique properties and reactivity, making it valuable in research and synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 104265-58-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,2,6 and 5 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 104265-58:
(8*1)+(7*0)+(6*4)+(5*2)+(4*6)+(3*5)+(2*5)+(1*8)=99
99 % 10 = 9
So 104265-58-9 is a valid CAS Registry Number.
104265-58-9Relevant academic research and scientific papers
CALCIUM CHANNEL INHIBITORS
-
Page/Page column 50, (2018/09/12)
The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases incl
TETRAHYDRONAPHTHALENE COMPOUNDS
-
Page/Page column 8-9, (2011/09/16)
The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R5, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
TETRAHYDRONAPHTHALENE COMPOUNDS
-
Page/Page column 18; 19, (2010/05/13)
The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R 5, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds ar
